BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023…
Mon, 04 Dec 2023 01:35:00 GMT Mainz Biomed N.V. (NASDAQ: MYNZ)’s stock price has gone rise by 15.79 in comparison to its previous close of 1.14, however, the company has experienced a 18.92% increase in its stock price over the ...
Wed, 29 Nov 2023 06:01:00 GMT Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed ...
Mon, 20 Nov 2023 15:12:00 GMT Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed . Certain statements made in this press release ...
